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Abstract
Background Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer that lacks ER/PR and HER2 
receptors. Hence, there is urgency in developing new or novel therapeutic strategies for treatment of TNBC. Our study shows 
that the Monocyte Chemoattractant Protein-1 (MCP-1) is a marker associated with TNBC and may play a key role in TNBC 
disease progression.
Experimental design ELISA method was used to measure secreted MCP-1, and mRNA levels were determined by Real-time 
PCR in numerous cancer cell lines, representing various breast cancer subtypes. Cellular invasiveness was determined by 
Boyden chamber assay.
Results Our data show that MCP-1 is upregulated in TNBC cell lines both transcriptionally as well as in secreted protein 
levels compared to ER-positive luminal cell line, MCF-7. Breast cancer patients, with Basal or Claudin-low subtypes, also 
showed high expression of MCP-1. MCP-1 treatment induced cell invasion in various breast cancer cell types, without 
affecting cell proliferation. Small molecule antagonists against Chemokine Receptor 2 (CCR2), cognate receptor for MCP-1 
as well as the MAP kinase pathway inhibitor U0126 negatively affected MCP-1 induced MCF-7 cell invasion. This sug-
gests that MCP-1-CCR2 axis may regulate invasiveness via the MAP Kinase pathway. Knocking down MCP-1 decreased 
cell invasion in TNBC cell line BT-549, along with downregulation of key epithelial to mesenchymal transition markers, 
N-cadherin and Vimentin.
Conclusion Our study suggests that MCP-1 mediated pathways could be potential therapeutic targets for the treatment of 
TNBC, and could reduce cancer health disparities.
Keywords MCP-1 · TNBC · Metastasis · MAP kinase
Introduction
Breast cancer is the second leading cause of mortality in 
women. According to SEER (surveillance, epidemiology, 
and end result program: seer.cancer.gov), more than 200 
thousand new breast cancer cases were diagnosed in 2016 
in the United States. The estimated death remains to be 
more than 40 thousand cases in the same year. Between 
the various histological subtypes of breast cancer, Triple-
negative breast cancer (TNBC) comprises only 15–20% 
of total breast cancer cases. However, thus far, TNBC is 
difficult to treat due to the lack of any targeted therapy [1, 
2]. TNBCs do not express estrogen (ER) or progesterone 
(PR) receptors or HER2 and lack specific biomarkers that 
could be correlated with disease incidence and progression 
[3]. TNBCs represent a significant health disparity as these 
occur at higher rates in African-American (AA) women 
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compared to European-American women. TNBCs are also 
diagnosed at younger ages (< 40 years) [4]. Thus far, the 
biological factors responsible for this health disparity in 
TNBC are unknown. Therefore, understanding the cellu-
lar or molecular nature of this health disparity is critical 
so that we can develop better treatment options for this 
type of breast cancer. Obesity is a well-known comorbidity 
in breast cancer and could contribute to this disparity as 
well. Obese African-American breast cancer patients have 
been shown to have lower disease-free survival compared 
with nonobese counterparts [5]. Obesity-related inflam-
mation has been shown to involve crosstalk between can-
cer cells and its microenvironment via chemokines that 
cause metastasis [6]. Monocyte Chemoattractant protein 1 
(MCP-1) is one such inflammatory chemokine implicated 
in cancer development and progression [7]. MCP-1 is a 
member of the C–C motif chemokine family. It is encoded 
from a locus at human Chromosome 17 and comprises of 
76 amino acids [8]. It is a 12kd protein that is secreted 
from the cell and binds to its receptor CCR2. The receptor 
for MCP-1 is a G-protein coupled receptor that activates 
downstream components upon ligand binding.
We have previously observed that MCP-1, along with 
GROα, serum levels were high in obese AA breast cancer 
patients compared with nonobese patients (unpublished 
observation). Cytokines like GROα was found to be highly 
expressed in TNBC and was associated with metastasis 
[9]. In our current study, we show that higher MCP-1 lev-
els are also associated with cell invasion and metastasis in 
breast cancer. Here we demonstrate that, MCP-1 is highly 
expressed in breast cancer cells. Importantly, the expres-
sion levels in TNBC tumor cells are higher compared with 
other subtypes of breast cancer cells. Although, MCP-1 
modestly affects cellular proliferation, it is a significant 
driver of cellular invasiveness in breast cancer. Our data 
shows MCP-1 regulating cell invasiveness in breast cancer 
via p44/42 MAP kinase (MAPK) pathway. Notably, our 
work indicates that MCP-1 is a potential biomarker for 
TNBC.
Materials and methods
Cell cultures, antibodies, and reagents
All cell lines were purchased from the ATCC (American 
type culture collection). MDA-MB-231, MCF-7, SK-BR-3, 
BT549, and T47D cells were grown in DMEM/F12 medium 
containing 10% FBS, 1 mM Glutamine, and antibiotics (Pen-
icillin/Streptomycin) in 5% CO2 incubator at 37 °C. HCC70, 
HCC1937, HCC1806, and HCC1395 were cultured similarly 
except when RPMI-1640 was used.
ELISA for human MCP‑1
ELISA was performed using the human CCL2/MCP-1 
Quantikine ELISA Kit (R&D Biosystems DCP00). Equal 
number of cells per condition was plated for overnight 
and then incubated with serum-free “Optimem” media for 
additional 24 h. The condition media was collected for 
measuring secreted MCP-1 protein level. MCP-1 levels 
(ng/ml) were normalized to 1 × 106 cells. The assay was 
independently performed twice and the level of MCP-1 in 
each cell line was mean from the two times’ measurements 
plus standard deviation.
RNA isolation and quantitative real‑time PCR
RNA was extracted from sub-confluent cells with RNA 
Bee (Tel-Test) and cDNA synthesis was performed using 
Quantabio cDNA synthesis master mix (95048) follow-
ing manufacturer instruction. The expression levels of a 
MCP-1 and MMP9 were tested along with an 18S con-
trol by qPCR with specific primers (supplement methods) 
in triplicates. The results were analyzed by the 2−ΔΔCt 
method to show relative expression over 18S as control 
gene. The RT-qPCR was performed twice with RNA 
extracted from two independent sub-confluent or treated 
cells for each experiment.
Boyden chamber invasion assay
8-μM pore 24-well Boyden chamber inserts were coated 
with Matrigel (BD Biosciences), and cells were plated on 
the top chamber. The bottom chamber contained serum-
free medium with the indicated amount of recombinant 
human MCP-1(rhMCP-1). When CCR2 antagonist and 
MEK inhibitors (U0126) were used, the cells were plated 
with the inhibitor on the top chambers. Each condition was 
plated in duplicates, and the assays were performed twice 
for each cell line. The invaded cells were counted using 
the 20X objective of a Leica DM IRB inverted micro-
scope from three randomly selected fields for each condi-
tion after 38 to 48 h as indicated in figure legends. The 
results are presented as the mean number of cells per field 
for each condition.
Western blotting
Total protein was extracted, and the concentration was 
measured using BCA protein assay (ThermoScientific). 
20–30 µg protein was separated on an 8–10% gel and 
western blot performed with antibodies as indicated in 
each figure. Western blot densitometry was performed 
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by normalizing the pixel intensities of the target proteins 
bands with the loading control. Densitometry was carried 
out utilizing the analysis function provide in the Li-Cor 
imaging software.
Transfection of shRNA/siRNA MCP‑1
BT-549 were transfected with lentiviral particles (Origene 
TL316716 V) at ~ 1 multiplicity of infection (MOI). BT549 
cells stably expressing MCP-1 shRNA were selected using 
0.75 µg/ml puromycin (Gibco Sterile Puromycin Dihydrochlo-
ride) for 3-weeks, and then the cells were maintained in com-
plete serum DMEM/F12 media with 0.25 µg/ml puromycin. 
siRNA pool for human MCP-1 (Dharmacon ON-TARGET 
plus L-007831-00-0005 and D-001810-10-05) and control 
pool were utilized to knockdown MCP-1 with Lipofectamine 
RNAi MAX (ThermoFisher 13778030) following manufac-
ture’s recommendation. After 72 h the siRNA knockdown 
MCP-1 cells were used for experiments.
Determining MMP9 activity by gelatin Zymography
10% Polyacrylamide gels were prepared with 1% Gelatin (final 
concentration) using Biorad apparatus. Cell lysate or cell-con-
ditioned media was mixed with gel loading buffer (4 × Bio-
rad) without DTT (Dithiothreitol) and boiling before loading. 
Gel separated samples were washed in 2.5% Tritron X-100 
(Renaturing buffer) twice for 30 min each on a shaking plat-
form. Renaturing buffer was then replaced with the developing 
buffer (50 mM TRIS, 0.2 M NaCl, 5 mM CaCl2) and gels 
were incubated at 37 °C for overnight. The following day, the 
gel was stained with Coommassie Blue R-250 for 30 min and 
de-stained with solution containing Methanol, Acetic acid, and 
Water (30: 10: 60). Picture was taken using a digital camera 
and processed with GIMP 2.8 on windows platform.
Statistical analysis, and analysis and usage 
of publicly available data
All data presented were confirmed by at least 2 independent 
set of experiments. The statistical significance was determined 
by Student’s t test, and p < 0.05 was considered as significance. 
METABRIC breast cancer data were accessed using MSKCC 
Cbioportal (www.cbiop otal.org). The relapse-free survival 
(RFS) was obtained from KMPLOT (www.kmplo t.com). 
The publicly available data were analyzed using Graph pad 
prism v7.
Results
MCP‑1 expression in breast cancer cells
We first asked whether MCP-1 expression levels vary in 
different breast cancer cell type. Clinical classification of 
breast cancer falls into four categories based on ER, PR, and 
Her2 expressions as ER/PR+ and Her2−, ER/PR/Her2+, 
ER/PR−/Her2+, and ER/PR/Her2− (triple negative). These 
categories or subtypes are further categorized based on 
gene expression as different molecular subtypes [10–12]. 
The categories are Luminal A (ER/PR-positive tumor falls 
under this subtype); Luminal B (ER/PR/HER2-positive 
tumor belongs to this subtype); HER2-enriched, basal-like 
and mesenchymal subtypes. Triple-negative breast cancer 
(TNBC) is more likely to fall under basal-like or mesenchy-
mal types [10]. In this study, we examined several of these 
cell types for MCP-1 expression. The TNBC/basal type cells 
Fig. 1  Expression of MCP-1 in breast cancer cells. a mRNA tran-
script levels of MCP-1 in breast cancer cells measured by qPCR 
with 18s as internal control. MCP-onefold enrichment is shown over 
MCF-7 luminal cell lines. RNA was isolated from the indicated cell 
lines in basal condition. b MCP-1 secretion in cell-conditioned media 
measured by ELISA against human MCP-1. Quantakine ELISA kit 
specific to human MCP-1 was used. Secreted MCP-1 levels are nor-
malized to  106 cells. MCP-1 transcript or secreted levels were meas-
ures in duplicate twice and data presented with standard deviation. 
*p < 0.05, t test
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include HCC1937, HCC11395, HCC70, and HCC1806, 
and the TNBC/mesenchymal-like cell lines are BT-549 and 
MDA-MB-231. MCF-7, BT474, and T47D were used as 
Luminal-type cells and SKBR3 cells represented as Her2-
positive or Her2-enriched tumor type. The highest MCP-1 
transcript levels were found to be in TNBC/mesenchymal 
type cells—BT549 and HCC1395 from our study (Fig. 1a). 
In addition, the secreted MCP-1 protein level was higher in 
most of TNBC cell lines compared with other types of cell 
lines (Fig. 1b).
As shown in Fig. 1b, the average secreted MCP-1 level in 
TNBCs was ~ 6 ng/ml/106 cells, whereas it was ~ 2 ng/ml/106 
cells in luminal-type or receptor-positive cells (p < 0.05 indi-
cated with asterisk). We also examined the canonical MCP-1 
receptor CCR2 [8] in different subtypes of breast cancer cell 
lines, and the CCR2 expression was found to vary among 
those lines (Fig. S1). Luminal cell lines, MCF-7 and T47D, 
Her2+ line, SKBR3 and TNBC lines, BT547 and HCC1937 
showed high levels of MCP-1.
MCP‑1 induces phosphorylation of p44/p42 and cell 
invasiveness
We first examined effect of MCP-1 in cell proliferation and 
the involvement of CCR2. We selected cells with low levels 
of MCP-1, such as MCF-7 and SKBR3, and induced the 
cells with recombinant human MCP-1 (rhMCP-1) followed 
by MTT assay. We also selected for high expression of both 
MCP-1 and CCR2 cell lines, such as BT549 and MDAMB-
231cells. The BT549 and MDA-MB231 cells were treated 
with CCR2 antagonist (anti CCR2) (Calbiochem CAS 
445479-97-0) followed by MTT assay. We did not find any 
significant effects of MCP-1 and CCR2 antagonist treatment 
on cell proliferation in those cells (Fig. S1A, B). Similarly, 
MCP-1 knockdown in BT549 cells also did not significantly 
change cell cycle stages as measured by propidium iodide 
staining (Fig. S2C). G0 stages changed to 55 from 60% after 
MCP-1 knockdown, possibly due to more cells being in S 
phage. A moderate effect was observed for S phase (18% 
vs. 26%) between scrambled shRNA and MCP-1 shRNA 
expressing cells (Fig. S2C right).
Next, we examined if MCP-1 could affect cell invasive-
ness. Low-expressing MCP-1 cell MCF-7 was selected and 
induced with rhMCP-1. It has been well known that activa-
tion of p44/42 by phosphorylation is associated with cell 
invasion and migration [13]. Therefore, we first examined 
the effect of MCP-1 on phosphorylation of MAPK. The data 
in Fig. 2a show phosphorylation of p44/p42 in MCF-7 cells 
was upregulated with the addition of 25 ng/ml rhMCP-1 for 
15 min. However, 50 ng–100 ng/ml rhMCP-1 did not signifi-
cantly increase the p44/p42 phosphorylation any further. The 
cell invasion in MCF-7 was also induced by MCP-1 for 48 h 
(Fig. 2b). To verify if MCP-1 cell invasion was via MAPK 
pathway, we treated cells with MEK inhibitor U0126, and 
the data showed MCP-1-induced cell invasion was signifi-
cantly blocked by U0126 treatment for 48 h (Fig. 2b). Since 
MCF-7 expresses high level of CCR2, we also examined 
if blocked CCR2 could inhibit the MCP-1 induced MAPK 
phosphorylation and cell invasion. MCF-7 cells were treated 
with anti CCR2 together with or without MCP-1, and then 
MAPK activity was determined by Western blot analysis. 
The data showed that blocking CCR2 inhibited endogenous 
level of phosphorylation of p44/p42 as well as MCP-1-in-
duced activation of MAPK in MCF-7 cells (Fig. 2c). As 
shown in Fig. 2c, the total MAPK was also inhibited by anti 
CCR2. MCP-1-induced cell invasion was also inhibited by 
anti CCR2 (Fig. 2d). The activation of p44/42 MAP kinases 
by MCP-1 was also observed in MDA-MB-231 cells, and 
this was detected using cell signaling protein array (Pathscan 
Array from Cell Signaling technologies) and verified with 
Western blot (Fig. S3A, B). As shown in Fig. S3C, the cell 
invasiveness of MDA-MB-231 was increased significantly 
upon rhMCP-1 induction, and this response was inhibited 
by anti CCR2. Similarly, MDA-MB-436 and MDA-MB-468 
cells upon treatment of rhMCP-1 also increased cell inva-
siveness significantly (Fig. S4). The data suggest that MCP-1 
could induce cell invasiveness via MAPK pathway without 
affecting cell proliferation in breast cancer cells.
Knocking down MCP‑1 inhibits phosphorylation 
of p44/p42 and cell invasiveness
To further confirm the role of MCP-1 in cell invasiveness, 
the knocking down of MCP-1 was performed in BT549 cells. 
BT549 has been reported as TNBC-mesenchymal/Claudin-
low type cells [14] and expresses high level of MCP-1 and 
CCR2 (Fig. 1 and Fig. S1). We first determined the effect of 
CCR2 antagonist on the phosphorylation of p44/42 levels in 
BT549 cells by treating the cells by increasing the concen-
tration of CCR2 antagonist. Phosphorylation of p44/p42 in 
BT549 was progressively reduced followed by increasing the 
dosage of the CCR2 antagonist treatment, without changes 
in total p44/p42 (Fig. 3a). The data suggest that MCP-1 
induced phosphorylation of p44/p42 via CCR2. Therefore, 
CCR2 could also be a potential target for inhibiting cell inva-
siveness in breast cancer.
Next, we knocked down (KD) MCP-1 in BT549 cells 
with shRNA as well as with siRNA targeting the coding 
region of MCP-1. Cells transfected with scrambled shRNA/
siRNA were used as control. The efficiency of MCP-1 KD 
with shRNA and siRNA was determined by RT-qPCR first 
(Fig. 3b left panel) and then the MCP-1 KD BT549 cells 
were subjected to invasion assay. A significantly decreased 
cell invasion was observed in the MCP-1 KD cells com-
pared with cells transfected with scrambled sequences (15 
vs. 24–26 invaded cells per field) (Fig. 3b right panel).
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MCP‑1 modulates Matrix Metalloprotease 9 (MMP9) 
and EMT associated protein in breast cancer
MMP activity is associated with cancer metastasis, as 
secreted MMPs help cancer cells to extravagate by digest-
ing extracellular matrix [15]. Interestingly, MMP9 has been 
implicated TNBC cells invasiveness. Therefore, we tested 
whether knocking down MCP-1 also affected the levels of 
MMP9. Our data showed that MMP9 transcripts in shMCP-1 
BT549 cells were downregulated (Fig. 4a left). Accordingly, 
MMP9 protein level was also reduced in shMCP-1 BT549 
cell lysate (Fig. 4a right). The data suggest that higher 
activity of MMP9 may be involved in matrix digestion in 
the cells. Next, we examined MMP9 activity by gelatin 
Fig. 2  MCP-1-CCR2 axis activating the p44/42 MAP kinase and pro-
moting cellular invasion. a MCP-1 treatment increases phosphoryla-
tion of p44/42 MAPK in MCF-7. Cells were serum starved overnight 
and treated with recombinant MCP-1 with the indicated doses, and 
cell lysate was prepared at 15  min time points (right). b Activated 
p44/42 MAPK is needed for MCP-1-mediated cellular invasiveness. 
MCF-7 cells treated with MEK inhibitor U0126 decreases cellular 
invasion in matrigel chamber assay. The invaded cells were counted 
after 48  h incubation. N = 3 Data shown with standard deviation, t 
test with for p < 0.05. c MCP-1 treatment results in phosphorylation 
of p44/42 via the CCR2 receptor. MCF-7 cells were pretreated with 
the 10 µM CCR2 antagonist for 2 h after 2 h of serum-free starvation. 
MCP-1 at the dose of 25 ng/ml was added in the presence or absence 
of the CCR2 antagonist. Cell lysate was prepared, and western blots 
were probed for phospho p44/42. d CCR2 is needed for MCP-1 medi-
ated invasion in Boyden chambers invasion assay. Cells were seeded 
in the presence or absence of CCR2 antagonist, and MCP-1 was 
used as the chemoattractant. The invaded cells were counted after 
38  h incubation (N = 3, Data shown with standard deviation, * and 
#p < 0.05, t test, * compared between control and rhMCP-1, # com-
pared between rhMCP-1 and rhMCP-1 with anti CCR2)
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zymography in cell lysate and in condition media. The data 
in Fig. 4b showed that shRNA knockdown MCP-1 reduced 
activity of MMP9 in both cell lysate and condition media.
It is known that cellular invasiveness is associated with 
gain of mesenchymal phenotype and loss of epithelial mor-
phology via a process called epithelial-to-mesenchymal tran-
sition (EMT). At the molecular level, cancer cells showing 
higher metastatic potential go through the process of EMT 
prior to metastases [16]. Therefore, we also examined role 
of MCP-1 in EMT. We have observed knockdown MCP-1 
in BT549 cells reduced N-cadherin and Vimentin, and when 
MCF-7 cells were treated with rhMCP-1, it downregulated 
E-cadherin and upregulated β-catenin (Fig.  4c). Those 
markers are well known as EMT-associated markers [17]. 
However, we did not observe any morphological changes or 
upregulation of EMT-related transcription factors in MCF-7 
cells upon MCP-1 treatment or BT549 cells upon knock-
down. Experiments with longer period of time treatment 
may be required for further validation.
Fig. 3  MCP-1 enhancing cel-
lular invasiveness in triple-
negative breast cancer cells. a 
MCP-1 receptor CCR2 regu-
lates phosphor p44/42 levels in 
BT549 cells. BT-549 cells were 
treated with CCR2 antagonist 
at the doses mentioned. After 
24 h, cell lysate was prepared, 
and western blots were probed 
for phospho p44/42. b Down-
regulating MCP-1 reduces 
invasion in BT549 cells. To 
knockdown MCP-1, BT549 
cells were transfected using 
shRNA (top) or siRNA pool 
(10 nM bottom). Knockdown 
levels are shown for a stable 
line expressing shMCP1 or 
for the treatment with siRNA 
using qPCR (N = 2, Data with 
Standard Deviation, *p < 0.05, t 
test). Boyden chambers invasion 
assay on the scrambled control 
and shMCP1 shown on the 
right. MCP-1 knockdown cells 
with siRNA were also subjected 
to Boyden chamber invasion 
assay. (N = 2, Data shown with 
standard deviation, *p < 0.05, 
t test)
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MCP‑1 is highly expressed in patients 
with Claudin‑low and basal types breast cancer
We have shown that MCP-1 expression is higher in breast 
cancer cell lines that are predominantly TNBC type (Fig. 1). 
Since several of these TNBC cells belong to Basal type and 
Claudin-low type cancers, we queried the METABRIC breast 
cancer dataset [18] for MCP-1 expression in those two sub-
types via Cbioportal [19]. Both basal and Claudin-low sub-
type breast cancer tissues showed significantly higher expres-
sion of MCP-1 mRNA in cancer tissues (Fig. 5a). To explore 
whether MCP-1 expression would have prognostic value, we 
also utilized data from KMPLOT [20] and queried relapse-free 
survival (RFS) in basal type breast cancer patients with high 
or low MCP-1 expression. The MCP-1 expression was meas-
ured by microarray in the dataset, and expression levels 1.5 
times higher than normal or noncancer tissue was used for 
assessing RFS. The data showed that RFS was significantly 
lower in patients with higher expression of MCP-1 (red line, 
median split) compared to those with lower expression of 
MCP-1 (black line) (Fig. 5b).
Fig. 4  MCP-1 affecting breast 
cancer invasiveness via MMP9 
and EMT associated proteins. 
a MMP9 transcript levels in 
BT549 cells expressing MCP-1 
shRNA or scrambled con-
trol. MMP9 mRNA level in 
shMCP-1 cells is shown with 
respect to control by qPCR, 
N = 2, Data with Standard 
Deviation, *p < 0.05, t test. 
MMP9 protein levels are shown 
on the right in the control and 
knockdown cells. b MMP9 
activity in BT549 cells upon 
MCP-1 knockdown. Gelatin 
zymography shown for cell 
lysate from control and shMCP1 
BT549 cells on the left. On 
the right is cell-conditioned 
media collected from the same 
cells. Proteins were separated 
on 10% gel containing 1% 
gelatin as substrate for MMP, as 
described in material Method. 
c EMT markers N-cadherin and 
Vimentin are shown in BT-549 
cells expressing MCP-1 shRNA 
by western blot (left) on cell 
lysate prepared from shMCP-1 
and scrambled control. E-cad 
and β-Catenin levels are shown 
for 100 ng/ml rhMCP-1 treated 
MCF-7 cells at 1 h relative to 
untreated control. Tubulin or 
GAPDH is shown as the loading 
control
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Discussion
A heterogeneous disease like breast cancer can manifest 
in various different clinical pathological subtypes. Among 
these different subtypes, TNBCs pose a challenge to breast 
cancer therapy because of its lack of identified target and 
propensity to relapse. We have shown that MCP-1 is upreg-
ulated in triple-negative breast cancer and can serve as a 
prognostic/diagnostic marker for TNBC cells. Interestingly, 
MCP-1 expression in individuals with breast cancer dif-
fer depending on the disease specific subtype [7]. Her2-
positive and TNBC (basal type) breast cancer cells show 
higher expression of MCP-1 than ER/PR-positive breast 
cancer cells (Fig. 5). Interestingly, MCP-1 has been shown 
to cooperate with RANTES to promote angiogenesis in 
breast cancer patients [21]. Thus, MCP-1 is possibly a part 
of a chemokine network that regulates breast tumorigen-
esis by augmenting inflammatory milieu. Inflammation in 
breast cancer is associated with poor outcome for patients, 
with advanced stage of the disease. In triple-negative breast 
cancer, inflammation plays an important role in modifying 
Immune environment. Inflammation usually is more permis-
sive for the cancer to grow and disseminate to distant organs.
In our work, we have shown, that MCP-1 upregulation 
can enhance cell invasion. In breast cancer cells, MCP-1 
mediated its effect via the canonical CCR2 receptor in an 
Fig. 5  Highly expressed 
MCP-1 in patients with basal 
and claudin-low type breast 
cancers. a METABRIC dataset 
showing expression of MCP-1 
in Basal and Claudin-low 
type breast cancers, which are 
predominantly TNBC type of 
breast cancer. mRNA expres-
sion in cancer tissue shown for 
Affymetrix U133A array data. 
b Relapse-free survival (RFS) 
probability in breast cancer 
patient with basal type intrinsic 
subtype (kmplot.com). d Pro-
posed model of MCP-1 action 
in breast cancer cells. Upregula-
tion of MCP-1 activates MAP 
kinase (p44/42) via activation 
of the CCR2 receptor on the 
breast cancer cell surface. 
Upregulation of β-catenin can 
also contribute to cell inva-
sion by possibly upregulating 
WNT TNBC cells shows higher 
expression of MCP-1, and can 
therefore be affected by MCP-1 
to be more invasive
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autocrine manner (Fig. 5c model). Our data also indicate that 
MCP-1 mediated cellular invasion works via the MAP kinase 
pathway. Since, MCP-1 is able to upregulate β-Catenin in 
MCF-7 cells, we posit that MCP-1 can also contribute to cell 
invasion by modifying Wnt in breast cancer cells (Fig. 5c). 
Interestingly, It has been shown that β-Catenin can trans-
activate MCP-1 promoter in breast cancer cells [22] Thus, 
a positive feedback loop may be able to transcriptionally 
upregulate MCP-1 in breast cancer. Our data provide evi-
dence for MCP-1 to be a prognostic marker for triple-nega-
tive breast cancer. Our findings could address health dispar-
ity in this area by opening up specific treatment avenues for 
patients with higher expression of MCP-1. MCP-1 antibody 
(ABN912) has been used in clinical trial for rheumatoid 
arthritis. However, the antibody therapy failed to show any 
clinical and immunological improvement with respect to 
placebo [23]. It would be interesting to see whether other 
antibodies could be a therapeutic option for women with 
TNBC, who also exhibit high MCP-1 levels. To date, the 
primary treatment option for TNBC is chemotherapy [2] and 
MCP-1 has been shown to protect breast cancer cells from 
apoptosis following treatment with chemotherapeutic agents 
[24]. Hence, MCP-1 antibodies or CCR2 receptor antagonist 
in combination with chemotherapy might be able to achieve 
pathologic complete response (pCR) as TNBCs are known 
to respond well to neoadjuvant chemotherapy. However, if 
pCR is not achieved, TNBCs tend to relapse more frequently 
compared to luminal A or B type breast cancer (TNBC 
paradox) [25]. MCP-1 could be one of the key factors in 
this phenomenon. This is because, chemotherapeutics are 
known to induce inflammatory cytokine like MCP-1 [26]. 
Higher MCP-1 expression/secretion following neoadjuvant 
chemotherapy can conceivably contribute to relapse as well 
as metastasis [27].
MCP-1 is also well known in macrophage-related migra-
tion and has been shown to be involved in breast cancer 
progression [28]. MCP-1 is one of the cytokines secreted 
from adipocytes that may precipitate inflammation. Both 
macrophages and adipocytes can contribute to tumor micro-
environment that permits tumor growth [29]. On the other 
hand, higher expression as well as secretion MCP-1 from 
TNBC cells can recruit macrophages in the tumor environ-
ment in vivo. Tumor associated macrophage show an M2 
phenotype, which helps the tumor to grow. In recent years, 
macrophages have been shown to aid tumor cells to extrava-
sate and metastasize. Thus, higher levels of MCP-1, in the 
tumor microenvironment, can be instrumental in enhancing 
cancer cell invasiveness by activating both autocrine and 
paracrine pathways [30]. Further work will be necessary to 
understand whether MCP-1 secreted from cancer cells and 
cells in the tumor micro environment (macrophages, adi-
pocytes, and fibroblast) will have different roles to play in 
terms to tumor initiation and maintenance.
Our data, thus far, indicates that higher MCP-1 level is 
associated with TNBC and has the potential to affect cell 
invasion by activating MAP kinase pathway in an autocrine 
manner. In accordance with that, we have found that higher 
MCP-1 levels in basal type breast cancer lead to lower sur-
vival in patient. TNBC is also a disease with significant 
health disparity. Younger African-American women have 
higher incidence of TNBC, resulting in increased mortality. 
Our findings could address this health disparity by open-
ing up specific treatment avenues for patients with higher 
expression of MCP-1. It would be interesting to see whether 
MCP-1 antibodies could be a therapeutic option for women 
with TNBC with high MCP-1 levels. For example, MCP-1 
antibody (ABN912) has been used in clinical trial for rheu-
matoid arthritis without much success [23]. This antibody 
can potentially be used to treat TNBC patients instead. Thus, 
the prognostic value of our finding can be utilized to design 
better therapies for TNBC patients with basal or mesenchy-
mal type of gene signature associated with the disease.
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